Loading...

The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

Conference: Meeting on the Med, 2023

2023-04-05T02:55:47-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s Meeting on the Med, April 12-14, 2023, in Barcelona, Spain. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.

Connect with our Advanced Therapy experts

  • Visit us through any of the numerous networking opportunities at Meeting on the Med 23′
  • Be sure to attend the ADVANCE sponsored workshop on April 12, 2023, at 4:45PM – 5:30PM CET |Location: Hotel Arts Barcelona (BioCentriq Ballroom: Gaudi 3)

You can register for Meeting on the Med below:

REGISTER HERE

(more…)

Read More

Article: The FDA and AAV-Based Gene Therapy Safety: What You Should Know

2023-07-11T09:35:59-04:00Cell & Gene Therapy|

Over the last couple of years, we have witnessed the tremendous potential of adeno-associated virus (AAV)-based gene therapies. However, there have been a few high-profile safety issues that have occurred, including deaths associated with AAV vector gene therapies that have raised safety concerns among the public and regulators. Don’t miss this great primer on AAV-based gene therapies by Precision’s Deb Phippard and Phil Cyr, including basic background on the vectors, safety concerns, strategies to mitigate safety issues, and recent FDA safety meetings.

(more…)

Read More

Conference: Gene Therapy for Rare Disorders (GTRD), 2023

2023-03-14T10:37:26-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s Gene Therapy for Rare Disorders on March 20-23, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below. 

  • Precision ADVANCE will have a plenary speaking position on March 21, 2023, 8:30 – 9:00 am.
  • Project Farma will be facilitating a plenary panel discussion ” Current Trends in Technical Operations for Rare Disorders” on March 21, 2023, 10:45 – 11:15 am.
  • Project Farma’s Tony Khoury (EVP, Project Farma) will be joining the Manufacturing track panel discussion, “Capacity versus Capability – Moving Towards Innovative Manufacturing Processes,” on March 21, 2023, 11:15 – 11:45 am.
  • Precision ADVANCE will hold a drinks reception on March 21, 2023, at 6:10 pm in the Grand & Liberty Ballroom.

Connect with our Advanced Therapy experts

  • Visit us at booth 13 in the exhibition area
  • Schedule in-person or virtual meetings by clicking here: https://bit.ly/precisionmedicinegrp
  • Attend our ADVANCE-sponsored Drinks Reception on March 21, 2023, at 6:10 PM ET

—

Plenary Speaking Position: Successfully Launching a Gene Therapy with Cynthia Pussinen & Dave Lennon
Precision ADVANCE | March 21, 2023, 8:30 – 9AM ET 

  • Key Takeaways
    • Identify active strategies to enable a smooth plan from preclinical development to commercialization
    • New approaches for regulatory approval and commercialization
    • Anticipating and overcoming potential hurdles specific to gene therapies
    • The future of the industry

Speakers:

  • Anshul Mangal: President (Project Farma & Precision ADVANCE)
  • Cynthia Pussinen: Former CTO (Spark Therapeutics Inc.)
  • Dave Lennon: CEO (Satellite Bio)

Panel Discussion: Current Trends in Technical Operations for Rare Disorders
Project Farma | March 21, 2023, 10:45-11:15AM ET

  • Key Takeaways
    • Current trends impacting manufacturing of gene therapies including capital markets, supply chain and technologies
    • Shifts in technical operations as a result of current trends
    • Opportunities and innovations in technical operations that can transform the industry

Speakers:

  • [Moderator] Charlie Harper: Vice President, Consulting (Project Farma)
  • Greg Gara: Senior Vice President (Project Farma)
  • Tony Khoury: Executive Vice President (Project Farma)
  • Eric Hacherl: Vice President, Manufacturing (Spark Therapeutics, Inc.)

Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Project Farma | March 21, 2023, 11:15 – 11:45AM ET

  • Greg Gara: Senior Vice President (Project Farma) to join
Read More

Article: Weathering the Storm: Cell and Gene’s Economic Downturn

2023-02-21T15:29:48-05:00Cell & Gene Therapy|

After record-setting milestones in fundraising over the past two years, the advanced therapy investment landscape is experiencing a natural correction. Precision’s Anshul Mangal and Dr. James M. Wilson outline in this The Medicine Maker article how industry leaders can ensure the advancement of innovative treatments for patients with #rarediseases by consolidating investments and prioritizing partnerships with patient advocacy organizations.

(more…)

Read More

On-Demand: Let’s Talk: Moving CGTx Clinical Development Forward in 2023

2023-03-09T12:12:46-05:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar will convene leading advanced therapy experts to discuss the future of CGTx clinical development. This discussion will be moderated by Teresa Pokladowski: Regional VP, Clinical Business Solutions (Precision for Medicine), and include insights from Kinnari Patel: President & COO (Rocket Pharmaceuticals), Suma Krishnan: Founder & President (Kystal Biotech), Dawn Buchanan: VP Clinical Operations (AffyImmune), and Ramona Repaczki-Jones: Executive Director, Commercial Treatment Center Operations, Cell Therapy (lovance Biotherapeutics, Inc).

(more…)

Read More

White Paper: What’s Next for Cell and Gene Therapies in 2023 and Beyond

2023-02-09T13:57:47-05:00Cell & Gene Therapy, Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished in recent years due to continued investor confidence. However, the present downturn in public markets has negatively affected that confidence, raising questions about the sector’s prospects for 2023 and beyond.

This white paper is based on a panel discussion at the Cell & Gene Meeting on the Mesa (October 11, 2022), sponsored by Precision ADVANCE, focusing on the future of advanced therapies. The panel included insights from the following industry leaders:

  • Anshul Mangal: President (Project Farma & Precision ADVANCE)
  • Stewart Abbot: Chief Scientific Officer (Turnstone Biologics)
  • Laura Lande-Diner: Chief Business Officer (Satellite Bio)
  • Robert Peters: Chief Scientific Officer (Ensoma)
  • Deborah Phippard: Chief Scientific Officer (Precision For Medicine)

(more…)

Read More

White Paper: State of the Union for Advanced Medicines

2023-02-09T10:41:09-05:00Cell & Gene Therapy, Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished over the last 2 to 5 years due to continued investor confidence. However, the recent downturn in public markets has undermined that confidence.

This white paper is based on a panel discussion, sponsored by Precision ADVANCE, featuring insights from diverse industry perspectives on the current state of the CGTx sector; the investment landscape; scientific and technical advances; progress in drug development, manufacturing, regulatory, pricing, and reimbursement; and expected key trends in 2023 and beyond. Hosted by Endpoints News, the panel included insights from the following industry leaders:

  • Anshul Mangal: President (Project Farma & Precision ADVANCE)
  • Dave Greenwald: Vice President of Business Development (Deerfield Management)
  • Rajul Jain: Managing Director (Vida Ventures)
  • Joseph LaBarge: Chief Executive Officer (Apertura Gene Therapy)
  • Adrian Woolfson: Executive Chairman, President and Co-Founder (Replay Bio)
  • Phil Cyr: Executive Vice President (Precision Value & Health)

(more…)

Read More

New Tech on the Rise: The Future of Cell and Gene Therapies Is Here

2023-01-19T07:10:40-05:00Cell & Gene Therapy|

Recent headlines suggest that the biotech industry as a whole is experiencing a downturn, yet in spite of this narrative the momentum for advanced therapies continues to persevere. Many companies in the cell and gene therapy space are dedicated to bringing these novel therapies to the patients who need them. In this article for PM360 Magazine, Precision’s Anshul Mangal explores the breakthroughs taking place in autologous cell therapies, non-viral delivery methods, and gene editing technologies that may improve patient access for life-saving treatments.

(more…)

Read More

On-Demand: The Hitchhiker’s Guide to CGTx in 2023

2023-01-30T14:51:25-05:00Cell & Gene Therapy, Events|

Cell & gene therapy advancement has increased at an immense rate over the past decade. With the right tools and guidance, patients can receive new forms of treatments. Staying up to date with progress in the field is as important as ever with the constant strive to improve technology, especially in areas like regulatory pathways, novel technologies, and CMC and manufacturing trends.

Sponsored by Precision ADVANCE, this Life Science Connect webinar will convene leading advanced therapy experts to discuss innovation and expectations for advanced therapies in 2023. This discussion will be moderated by Andy Kinley (VP of Innovation & Clinical Science, Precision for Medicine), and include insights from Peter Andersen (CSO, Vita Therapeutics), Deb Phippard (CSO, Precision for Medicine), Palani Palaniappan (CTO, Flagship Pioneering), Phil Cyr (SVP, Precision Value & Health), and Charlie Harper (VP, Project Farma).

(more…)

Read More
Load More Posts

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

© Precision Medicine Group, LLC.
All Rights Reserved.